| Autor: |
Angélique, Vienot, Hortense, Chevalier, Clément, Bolognini, Elisabeta, Gherga, Elodie, Klajer, Aurélia, Meurisse, Marine, Jary, Stefano, Kim, Christelle, d'Engremont, Thierry, Nguyen, Fabien, Calcagno, Hamadi, Almotlak, Francine, Fein, Meher, Nasri, Syrine, Abdeljaoued, Anthony, Turpin, Christophe, Borg, Dewi, Vernerey |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
World Journal of Gastrointestinal Oncology |
| ISSN: |
1948-5204 |
| Popis: |
BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibility in colorectal cancer. AIM To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical practice. METHODS Analyses were derived from all consecutive aPDAC patients treated in L1 between January 2011 and December 2017 in two French institutions, with either FOLFOXIRI (n = 165) or FOLFIRINOX (n = 124) regimens. FOLFOXIRI consisted of irinotecan (165 mg/m2), oxaliplatin (85 mg/m2), leucovorin (200 mg/m2) and 5-fluorouracil (3200 mg/m2 as a 48-h continuous infusion) every 2 wk. Ninety-six pairs of patients were selected through propensity score matching, and clinical outcomes of the two treatment regimens were compared. RESULTS Median overall survival was 11.1 mo in the FOLFOXIRI and 11.6 mo in the FOLFIRINOX cohorts, respectively. After propensity score matching, survival rates remained similar between the two regimens in terms of overall survival (hazard ratio = 1.22; P = 0.219) and progression-free survival (hazard ratio = 1.27; P = 0.120). The objective response rate was 37.1% in the FOLFOXIRI group vs 47.8% in the FOLFIRINOX group (P = 0.187). Grade 3/4 toxicities occurred in 28.7% of patients in the FOLFOXIRI cohort vs 19.5% in the FOLFIRINOX cohort (P = 0.079). FOLFOXIRI was associated with a higher incidence of grade 3/4 digestive adverse events. Hematopoietic growth factors were used after each chemotherapy cycle and the low hematological toxicity rates were below 5% with both regimens. CONCLUSION FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with FOLFIRINOX. The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
